|
1
|
dos Santos NA, Carvalho Rodrigues MA,
Martins NM and dos Santos AC: Cisplatin-induced nephrotoxicity and
targets of nephroprotection: An update. Arch Toxicol. 86:1233–1250.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arany I and Safirstein RL: Cisplatin
nephrotoxicity. Semin Nephrol. 23:460–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perazella MA and Moeckel GW:
Nephrotoxicity from chemotherapeutic agents: Clinical
manifestations, pathobiology, and prevention/therapy. Semin
Nephrol. 30:570–581. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Launay-Vacher V, Rey JB, Isnard-Bagnis C,
Deray G and Daouphars M: European Society of Clinical Pharmacy
Special Interest Group on Cancer Care: Prevention of cisplatin
nephrotoxicity: State of the art and recommendations from the
European society of clinical pharmacy special interest group on
cancer care. Cancer Chemother Pharmacol. 61:903–909. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bause AS and Haigis MC: SIRT3 regulation
of mitochondrial oxidative stress. Exp Gerontol. 48:634–639. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haigis MC and Guarente LP: Mammalian
sirtuins-emerging roles in physiology, aging, and calorie
restriction. Genes Dev. 20:2913–2921. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sack MN: The role of SIRT3 in
mitochondrial homeostasis and cardiac adaptation to hypertrophy and
aging. J Mol Cell Cardiol. 52:520–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lombard DB, Alt FW, Cheng HL, Bunkenborg
J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D,
Murphy A, et al: Mammalian Sir2 homolog SIRT3 regulates global
mitochondrial lysine acetylation. Mol Cell Biol. 27:8807–8814.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dang W: The controversial world of
sirtuins. Drug Discov Today Technol. 12:e9–e17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahn BH, Kim HS, Song S, Lee IH, Liu J,
Vassilopoulos A, Deng CX and Finkel T: A role for the mitochondrial
deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad
Sci USA. 105:pp. 14447–14452. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qiu X, Brown K, Hirschey MD, Verdin E and
Chen D: Calorie restriction reduces oxidative stress by
SIRT3-mediated SOD2 activation. Cell Metab. 12:662–667. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirschey MD, Shimazu T, Goetzman E, Jing
E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S,
Ilkayeva OR, et al: SIRT3 regulates mitochondrial fatty-acid
oxidation by reversible enzyme deacetylation. Nature. 464:121–125.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bellizzi D, Rose G, Cavalcante P, Covello
G, Dato S, De Rango F, Greco V, Maggiolini M, Feraco E, Mari V,
Franceschi C, et al: A novel VNTR enhancer within the SIRT3 gene, a
human homologue of SIR2, is associated with survival at oldest
ages. Genomics. 85:258–263. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koentges C, Bode C and Bugger H: SIRT3 in
cardiac physiology and Disease. Front Cardiovasc Med. 3:382016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zeng H, Vaka VR, He X, Booz GW and Chen
JX: High-fat diet induces cardiac remodelling and dysfunction:
Assessment of the role played by SIRT3 loss. J Cell Mol Med.
19:1847–1856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng H, He X, Hou X, Li L and Chen JX:
Apelin gene therapy increases myocardial vascular density and
ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3.
American journal of physiology. Am J Physiol Heart Circ Physiol.
306:H585–H597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Allison SJ and Milner J: SIRT3 is
pro-apoptotic and participates in distinct basal apoptotic
pathways. Cell Cycle. 6:2669–2677. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiao X, Li Y, Zhang T, Liu M and Chi Y:
Role of Sirtuin3 in high glucose-induced apoptosis in renal tubular
epithelial cells. Biochem Biophys Res Commun. 480:387–393. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koyama T, Kume S, Koya D, Araki S, Isshiki
K, Chin-Kanasaki M, Sugimoto T, Haneda M, Sugaya T, Kashiwagi A, et
al: SIRT3 attenuates palmitate-induced ROS production and
inflammation in proximal tubular cells. Free Radic Biol Med.
51:1258–1267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramesh G and Reeves WB: TNF-alpha mediates
chemokine and cytokine expression and renal injury in cisplatin
nephrotoxicity. J Clin Invest. 110:835–842. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang KP, Park SK, Kim DH, Sung MJ, Jung
YJ, Lee AS, Lee JE, Ramkumar KM, Lee S, Park MH, et al: Luteolin
ameliorates cisplatin-induced acute kidney injury in mice by
regulation of p53-dependent renal tubular apoptosis. Nephrol Dial
Transplant. 26:814–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang KP, Kim DH, Jung YJ, Lee AS, Lee S,
Lee SY, Jang KY, Sung MJ, Park SK and Kim W: Alpha-lipoic acid
attenuates cisplatin-induced acute kidney injury in mice by
suppressing renal inflammation. Nephrol Dial Transplant.
24:3012–3020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jung YJ, Lee JE, Lee AS, Kang KP, Lee S,
Park SK, Lee SY, Han MK, Kim DH and Kim W: SIRT1 overexpression
decreases cisplatin-induced acetylation of NF-κB p65 subunit and
cytotoxicity in renal proximal tubule cells. Biochem Biophys Res
Commun. 419:206–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP,
Lee S, Park SK, Han MK, Lee SY, Ramkumar KM, et al: SIRT1
activation by resveratrol ameliorates cisplatin-induced renal
injury through deacetylation of p53. Am J Physiol Renal Physiol.
301:F427–F435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morigi M, Perico L, Rota C, Longaretti L,
Conti S, Rottoli D, Novelli R, Remuzzi G and Benigni A: Sirtuin
3-dependent mitochondrial dynamic improvements protect against
acute kidney injury. J Clin Invest. 125:715–726. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim D, Lee AS, Jung YJ, Yang KH, Lee S,
Park SK, Kim W and Kang KP: Tamoxifen ameliorates renal
tubulointerstitial fibrosis by modulation of estrogen receptor
alpha-mediated transforming growth factor-β1/Smad signaling
pathway. Nephrol Dial Transplant. 29:2043–2053. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pabla N and Dong Z: Cisplatin
nephrotoxicity: Mechanisms and renoprotective strategies. Kidney
Int. 73:994–1007. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Havasi A and Borkan SC: Apoptosis and
acute kidney injury. Kidney Int. 80:29–40. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fischler R, Meert AP, Sculier JP and
Berghmans T: Continuous renal replacement therapy for acute renal
failure in patients with cancer: A well-tolerated adjunct
treatment. Front Med (Lausanne). 3:332016.PubMed/NCBI
|
|
30
|
Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS,
Lee S, Kim W, Davaatseren M, Hwang JT, Kim HJ, et al: Genistein
protects the kidney from cisplatin-induced injury. Kidney Int.
74:1538–1547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park MS, De Leon M and Devarajan P:
Cisplatin induces apoptosis in LLC-PK1 cells via activation of
mitochondrial pathways. J Am Soc Nephrol. 13:858–865.
2002.PubMed/NCBI
|
|
32
|
Perico L, Morigi M and Benigni A:
Mitochondrial Sirtuin 3 and Renal Diseases. Nephron. 134:14–19.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marfe G, Tafani M, Indelicato M,
Sinibaldi-Salimei P, Reali V, Pucci B, Fini M and Russo MA:
Kaempferol induces apoptosis in two different cell lines via Akt
inactivation, Bax and SIRT3 activation, and mitochondrial
dysfunction. J Cell Biochem. 106:643–650. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sundaresan NR, Samant SA, Pillai VB,
Rajamohan SB and Gupta MP: SIRT3 is a stress-responsive deacetylase
in cardiomyocytes that protects cells from stress-mediated cell
death by deacetylation of Ku70. Mol Cell Biol. 28:6384–6401. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pillai VB, Samant S, Sundaresan NR,
Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP,
Gius D and Gupta MP: Honokiol blocks and reverses cardiac
hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun.
6:66562015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Averett C, Arora S, Zubair H, Singh S,
Bhardwaj A and Singh AP: Molecular targets of honokiol: A promising
phytochemical for effective cancer management. Enzymes. 36:175–193.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumar A, Kumar Singh U and Chaudhary A:
Honokiol analogs: A novel class of anticancer agents targeting cell
signaling pathways and other bioactivities. Future Med Chem.
5:809–829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zordoky BN, Robertson IM and Dyck JR:
Preclinical and clinical evidence for the role of resveratrol in
the treatment of cardiovascular diseases. Biochim Biophys Acta.
1852:1155–1177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen T, Li J, Liu J, Wang S, Liu H, Zeng
M, Zhang Y and Bu P: Activation of SIRT3 by resveratrol ameliorates
cardiac fibrosis and improves cardiac function via the TGF-β/Smad3
pathway. Am J Physiol Heart Circ Physiol. 308:H424–H434. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alhazzazi TY, Kamarajan P, Xu Y, Ai T,
Chen L, Verdin E and Kapila YL: A Novel Sirtuin-3 Inhibitor,
LC-0296, inhibits cell survival and proliferation, and promotes
apoptosis of head and neck cancer cells. Anticancer Res. 36:49–60.
2016.PubMed/NCBI
|
